Recursion Pharmaceuticals (RXRX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Recursion Pharmaceuticals (RXRX) is Neutral.

The composite score behind that read is -0.13, weighing +0.42 of bullish evidence against -0.26 bearish.

Recursion Pharmaceuticals last closed at $4.63, -3.14% on the session.

Against the IVW growth benchmark the position is -3.75% over the forecast window.

The read is built from 11 underlying insights — 2 bullish and 9 bearish.

Agreement across those insights is 82%.

15 graded predictions for RXRX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Recursion Pharmaceuticals in the 18th percentile on return on equity, where 100 is best.

Recursion Pharmaceuticals is classified under Health Care / Biotechnology, with a market capitalisation of $2.56B.

StockMap tracks Recursion Pharmaceuticals as the 75th largest of the 365 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 190 Moderate Underperform, 164 Neutral and 11 Strong Underperform.

On that composite Recursion Pharmaceuticals ranks 101st of 365 in the group, against a group median of -0.21.